Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type I alpha-2 chain (COL1A2)
- Target
- COL1A2
- Molecular classification
- Other (structural extracellular matrix protein, fibrillar collagen)
01
Overview
The **collagen type I alpha-2 chain** is a polypeptide encoded by the COL1A2 gene. It is one of the two major chains (along with the alpha-1 chain) that assemble into the triple helix forming type I collagen, the most abundant structural protein in the human body. Type I collagen is fundamental to the integrity and strength of connective tissues such as bone, skin, tendon, and the sclera of the eye. The alpha-2 chain combines with two alpha-1 chains to form a procollagen triple helix that is processed and crosslinked into fibrils, which give tissues their tensile strength. Mutations in COL1A2 are associated with heritable connective tissue disorders, notably various forms of osteogenesis imperfecta and Ehlers-Danlos syndrome. While critical for tissue structure and health, the alpha-2 chain is not a typical drug target but rather a structural molecule whose defects underlie several genetic diseases.
- Other names
- Collagen alpha-2(I) chainAlpha-2 type I collagen
02
Mechanism of action
Not applicable (no direct-acting drugs on this chain)
03
Biological functions
Extracellular matrix structural supportCollagen fibril organizationBlood vessel developmentSkeletal system developmentSkin morphogenesisRegulation of blood pressure
04
Disease associations
Osteogenesis imperfectaEhlers-Danlos syndromeIdiopathic osteoporosisAtypical Marfan syndromeCardiac-valvular defects
05
Safety considerations
Targeting type I collagen can pose risks of impairing tissue integrity, healing, and bone strength; no approved therapies directly modulate the collagen type I alpha-2 chain for these reasons
06
Interacting drugs
No direct therapeutic drugs specifically target COL1A2 or the collagen type I alpha-2 chain as a primary drug target. Collagen-modifying therapies (e.g., bisphosphonates in osteogenesis imperfecta) exist, but these do not directly engage the chain as a classical drug target
07
Biomarkers
Mutational analysis in COL1A2 can be used for the diagnosis of osteogenesis imperfecta and certain subtypes of Ehlers-Danlos syndrome
Beyond the preview
Go deeper on Collagen type I alpha-2 chain (COL1A2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Collagen type I alpha-2 chain (COL1A2).